Therapeutic targeting of integrin ?v?6 in breast cancer

Moore, Kate M.; Thomas, Gareth J.; Duffy, Stephen W.; Warwick, Jane; Gabe, Rhian; Chou, Patrick; Ellis, Ian O.; Green, Andrew R.; Haider, Syed; Brouilette, Kellie; Saha, Antonio; Vallath, Sabari; Bowen, Rebecca; Chelala, Claude; Eccles, Diana; Tapper, William J.; Thompson, Alastair M.; Quinlan, Phillip; Jordan, Lee; Gillett, Cheryl; Brentnall, Adam; Violette, Shelia; Weinreb, Paul H.; Kendrew, Jane; Barry, Simon T.; Hart, Ian R.; Louise Jones, J.; Marshall, John F.

Abstract

Background

Integrin αvβ6 promotes migration, invasion, and survival of cancer cells; however, the relevance and role of αvβ6 has yet to be elucidated in breast cancer.

Methods

Protein expression of integrin subunit beta6 (β6) was measured in breast cancers by immunohistochemistry (n > 2000) and ITGB6 mRNA expression measured in the Molecular Taxonomy of Breast Cancer International Consortium dataset. Overall survival was assessed using Kaplan Meier curves, and bioinformatics statistical analyses were performed (Cox proportional hazards model, Wald test, and Chi-square test of association). Using antibody (264RAD) blockade and siRNA knockdown of β6 in breast cell lines, the role of αvβ6 in Human Epidermal Growth Factor Receptor 2 (HER2) biology (expression, proliferation, invasion, growth in vivo) was assessed by flow cytometry, MTT, Transwell invasion, proximity ligation assay, and xenografts (n ≥ 3), respectively. A student’s t-test was used for two variables; three-plus variables used one-way analysis of variance with Bonferroni’s Multiple Comparison Test. Xenograft growth was analyzed using linear mixed model analysis, followed by Wald testing and survival, analyzed using the Log-Rank test. All statistical tests were two sided.

Results

High expression of either the mRNA or protein for the integrin subunit β6 was associated with very poor survival (HR = 1.60, 95% CI = 1.19 to 2.15, P = .002) and increased metastases to distant sites. Co-expression of β6 and HER2 was associated with worse prognosis (HR = 1.97, 95% CI = 1.16 to 3.35, P = .01). Monotherapy with 264RAD or trastuzumab slowed growth of MCF-7/HER2-18 and BT-474 xenografts similarly (P < .001), but combining 264RAD with trastuzumab effectively stopped tumor growth, even in trastuzumab-resistant MCF-7/HER2-18 xenografts.

Conclusions

Targeting αvβ6 with 264RAD alone or in combination with trastuzumab may provide a novel therapy for treating high-risk and trastuzumab-resistant breast cancer patients.

• Journal Article Type: Article
• Acceptance Date: May 13, 2014
• Online Publication Date: Jun 28, 2014
• Publication Date: Jun 30, 2014
• Deposit Date: Apr 24, 2018
• Publicly Available Date: Nov 6, 2018
• Print ISSN: 0027-8874
• Electronic ISSN: 1460-2105
• Publisher: Oxford University Press
• Peer Reviewed: Peer Reviewed
• Volume: 106
• Issue: 8
• Article Number: dju169
• Pages: 1-14
• DOI: https://doi.org/10.1093/jnci/dju169
• Public URL: https://nottingham-repository.worktribe.com/output/1118112
• Publisher URL: https://academic.oup.com/jnci/article/106/8/dju169/911122
• PMID: 24974129